Nasdaq
$20.53▼ 0.10%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.81BShares out 88.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
30- 4d agoAfter-hours26.10.21 06:354Ownership#●●●
Mineralys Therapeutics, Inc.
Reporting person Kristine Peterson filed a Form 4 regarding changes in beneficial ownership of Mineralys Therapeutics, Inc. securities as of October 19, 2026.…more
$20.53-0.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoAfter-hours26.10.21 06:333Ownership
Mineralys Therapeutics, Inc.
Kristine Peterson, an executive at Mineralys Therapeutics, has filed a Power of Attorney authorizing designated representatives to handle her SEC reporting obligations. This filing serves as an administrative measure to ensure timely compliance with securities laws regarding her filings as a company officer.…more
$20.53-0.10%vs prev closeView filingShare - 4d agoAfter-hours26.10.21 06:324Ownership
Mineralys Therapeutics, Inc.
Lonnel Coats, an executive at Mineralys Therapeutics, reported changes in beneficial ownership of company securities via SEC Form 4 on October 19, 2026. This filing formalizes the recent adjustment in the insider's equity holdings.…more
$20.53-0.10%vs prev closeView filingShare
29 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 07:40#●●●#●●●
Mineralys Therapeutics Presents New Lorundrostat Clinical Data
Mineralys Therapeutics reported positive Phase 3 clinical trial results for lorundrostat, demonstrating significant blood pressure reduction and improved albuminuria in patients with hypertension and chronic kidney disease. The drug is currently under FDA review with a target decision date of December 22, 2026.…more
$20.53-0.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 5d agoAfter-hours26.10.20 05:05
●●●●●●●● ●●●●● ●●●●●●
Mineralys Therapeutics has appointed two new board members with extensive commercial experience ahead of the PDUFA target date for its hypertension drug, lorundrostat. The company stated these appointments are intended to support its transition into a commercial-stage organization.…more
$20.53-0.10%vs prev close - 10.9Pre-market26.10.09 22:00
●●●●●●●● ●●●●● ●●●●●●
Mineralys Therapeutics announced positive results from its Phase 3 and Phase 2 trials for the hypertension drug lorundrostat, demonstrating significant blood pressure reduction. However, this presentation of clinical data does not represent immediate revenue or regulatory approval.…more
$20.53-0.10%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report